Study comparing new targeted drug plus chemo vs osimertinib for lung cancer with brain tumors
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted therapy called furmonertinib combined with chemotherapy against the current standard osimertinib for people with a specific type of non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to find a better treatment option for patients whose cancer cells have a common EGFR mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-squamous non-small cell lung cancer that has spread to the brain.
- Your cancer cells have an EGFR mutation (either exon 19 deletion or L858R).
- You have not had any prior cancer treatment for advanced or metastatic lung cancer.
- You are at least 18 years old and in generally good health (able to take care of yourself).
- You have at least one brain tumor and one tumor outside the brain that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two targeted therapy drugs, furmonertinib and osimertinib, at higher doses to see which works better for advanced EGFR-mutant lung cancer that has spread to the brain. It may be an option if you have stable brain metastases and haven't had prior EGFR-targeted treatment.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This trial compares two doses of the targeted drug furmonertinib (80 mg vs 160 mg) combined with chemotherapy for people with EGFR-mutated lung cancer that has spread to the brain. It aims to find out which dose works better and is safer.
This trial tests a high-dose targeted pill, furmonertinib, in people with EGFR-mutated non-small cell lung cancer that has spread to the brain. It aims to better control both the lung cancer and the brain metastases by targeting a specific gene change.
This trial tests a combination of two targeted therapy drugs (furmonertinib and anlotinib) for people with advanced lung adenocarcinoma that has spread to the brain and has an EGFR mutation. The goal is to see if this combination can shrink or control the brain tumors.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
Hear when a new NSCLC Patients With Brain Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.